Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment

Marzia Del Re, Tiziana Latiano, Leonardo Fidilio, Giuliana Restante, Franco Morelli, Evaristo Maiello, Romano Danesi

Research output: Contribution to journalArticle

Abstract

The standard treatment of testicular germ cell tumors is based on the combination of bleomycin, etoposide, and cisplatin (PEB). However, this treatment may be associated with severe adverse reactions, such as hematological and non-hematological toxicities. Here, we report a case of a patient suffering from severe PEB-related toxicities, to whom pharmacogenetic analyses were performed, comprising a panel of genes involved in PEB metabolism. The analysis revealed the presence of a complex pattern of polymorphisms in GSTP1, UGT1A1 (TA)6/7, UGT1A7, and ABCB1. The present case shows that a pharmacogenetic approach can help in the management of adverse drug reactions in order to predict, prevent, and personalize treatments.

Original languageEnglish
Pages (from-to)69-73
Number of pages5
JournalEPMA Journal
Volume8
Issue number1
DOIs
Publication statusPublished - Mar 7 2017

Keywords

  • Bleomycin-etoposide-cisplatin combined treatment
  • Pharmacogenetics
  • Polymorphisms
  • Precision medicine
  • Predictive preventive personalized medicine
  • Testicular germ cell cancer
  • Toxicity

ASJC Scopus subject areas

  • Drug Discovery
  • Health Policy
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment'. Together they form a unique fingerprint.

  • Cite this